Title : Upregulation of mTORC2 activation by the selective agonist of EPAC, 8-CPT-2Me-cAMP, in prostate cancer cells: assembly of a multiprotein signaling complex.

Pub. Date : 2012 May

PMID : 22173835






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Here we show in 1-LN prostate cancer cells that 8-CPT-2Me-cAMP causes a dose-dependent increase in Epac1, p-Akt(T308) , p-Akt(S473) , but not p-CREB. Cyclic AMP AKT serine/threonine kinase 1 Homo sapiens
2 Here we show in 1-LN prostate cancer cells that 8-CPT-2Me-cAMP causes a dose-dependent increase in Epac1, p-Akt(T308) , p-Akt(S473) , but not p-CREB. Cyclic AMP AKT serine/threonine kinase 1 Homo sapiens
3 Silencing Rictor gene expression by RNAi significantly suppressed 8-CPT-2Me-cAMP-induced phosphorylation of Akt at Ser(473) . Cyclic AMP AKT serine/threonine kinase 1 Homo sapiens
4 Pretreatment of these cells with the PI 3-Kinase inhibitor LY294002 significantly suppressed 8-CPT-2Me-cAMP-dependent p-Akt(S473) and p-Akt(S473) kinase activities, and both effects were rapamycin insensitive. Cyclic AMP AKT serine/threonine kinase 1 Homo sapiens
5 Pretreatment of these cells with the PI 3-Kinase inhibitor LY294002 significantly suppressed 8-CPT-2Me-cAMP-dependent p-Akt(S473) and p-Akt(S473) kinase activities, and both effects were rapamycin insensitive. Cyclic AMP AKT serine/threonine kinase 1 Homo sapiens